The b-catenin protein is at the core of the canonical Wnt signalling pathway. Wnt stimulation leads to b-catenin accumulation, nuclear translocation and interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to regulate genes important for embryonic development and proliferation. Wnt/b-catenin can promote stem cell self-renewal and is dysregulated in colon carcinoma. We have examined the role of the Wnt pathway in the development of acute myeloid leukaemia (AML) and find that the b-catenin protein is readily detected in primary AML samples. Using transfection of a TCF/LEF reporter construct into primary AML cells and normal human progenitors, we find increased reporter activity in 16/25 leukaemia samples. Retrovirally mediated expression of a mutant active b-catenin in normal progenitors preserves CD34 expression and impairs myelomonocytic differentiation. Activation of TCF/LEF signalling decreases factor withdrawal-induced apoptosis of normal progenitors. A significant proportion of AML cases show aberrant expression of components of the Wnt pathway including Wnt-1, Wnt-2b and LEF-1. These results provide evidence for the involvement of the Wnt/b-catenin pathway in the pathogenesis of AML.
Introduction
The Wnt family consists of at least 19 secreted proteins that regulate developmental processes (Smalley and Dale, 1999) . The modules that transduce Wnt signals are highly conserved throughout evolution and in the canonical Wnt pathway a central role is played by the b-catenin protein. b-Catenin was first identified as a protein that links cell adhesion molecules of the cadherin family to the cortical actin cytoskeleton, but later genetic and biochemical analyses also placed it within the Wnt pathway (Conacci-Sorrell et al., 2002) . In the steady state, levels of free (non-cadherin-bound) cytosolic b-catenin are suppressed by proteasomal degradation. This process is regulated by a complex of proteins that include axin, adenomatous polyposis coli (APC), casein kinase 1 (CK1a) and glycogen synthase kinase-3 (GSK-3b) (Giles et al., 2003) . Phosphorylation of b-catenin by CK1a and GSK-3b on key N-terminal residues targets it for ubiquitination and breakdown in the proteasome. Wnt binding to cognate Frizzled receptors results in the activation of the Dishevelled protein (Dsh) by an unknown mechanism. Dsh suppresses the phosphorylation of b-catenin, resulting in its accumulation and translocation to the nucleus. Here it binds to transcription factors of the T-cell factor/ lymphoid enhancer factor (TCF/LEF) family and stimulates the expression of target genes (Kikuchi, 2003) .
The Wnt/b-catenin pathway is known to be involved in tumour formation in several cell types. Truncation or loss of the APC protein as seen in colorectal cancer results in the accumulation of b-catenin and increased expression of the cell cycle regulators c-Myc and cyclin D1 (Bienz and Clevers, 2000; Giles et al., 2003; Kikuchi, 2003) . Inactivating mutations of axin, with resulting activation of b-catenin signalling, have been described in hepatic carcinoma. Point mutations in the N-terminal regulatory region of b-catenin are found in a number of epithelial tumours. These prevent phosphorylation or ubiquitination of b-catenin and are often found in colorectal tumours that do not have mutations in APC (Giles et al., 2003; Kikuchi, 2003) . Recently, overexpression of Dsh has been implicated in the development of mesothelioma and lung cancer (Uematsu et al., 2003a, b) .
In haemopoiesis, murine yolk sac and fetal liver progenitors have been shown to express Wnt-5a and -10b as well as Frizzled receptors (Austin et al., 1997) . Incubation of fetal liver progenitors with conditioned media from cell lines expressing Wnt-1, -5a or -10b led to amplification of cell number. Similar results were reported by Van Den Berg et al. (1998) , who found expansion of colony forming cells in response to coculture of progenitors with Wnt expressing feeder cells. Wnt proteins are also mitogenic for B-cell precursors, and the LEF-1 transcription factor plays a key role in B-cell development (Reya et al., 2000) . Recently, Weissman's group has shown that expression of a mutant activated b-catenin in murine haemopoietic progenitors results in an expansion of the haemopoietic stem cell (HSC) pool and that inhibition of Wnt signalling results in reduced HSC function . In this study, we have looked for activation of the Wnt/b-catenin pathway in acute myeloid leukaemia (AML). We have chosen to investigate primary material for its biological relevance; cell lines may not give an accurate representation of normal progenitor biology or of the molecular pathogenesis of AML. This latter point was recently well illustrated by Quentmeier et al. (2003) , who showed that mutations of the Flt3 tyrosine kinase are rare in AML cell lines (four of 69), whereas large studies using primary material have indicated that such mutations are present in over 30% of cases (Kottaridis et al., 2001) .
Results

Expression of b-catenin in normal and leukaemic myeloid cells
First we examined expression of b-catenin protein in normal human CD34 þ progenitors induced to undergo myeloid differentiation in liquid culture in response to cytokines SCF, IL-3, G-CSF and GM-CSF. Under these conditions, there is extensive cell division and differentiation with loss of expression of CD34 and acquisition of maturation markers such as CD11b (Watts et al., 2002) (Figure 1 ). We found that freshly isolated CD34 þ cells expressed readily detectable (Figure 1 ). At this stage, the cells have the morphological appearance of myeloblasts -the majority of cells have downregulated CD34, express CD33 but there has not yet been a significant increase in CD11b expression. We compared the expression of b-catenin in 26 cases of AML with that in normal myeloid precursors, which had been in CD34 þ cell-initiated myeloid expansion culture for 6 days. Unlike the case in normal progenitors, we found a variable level of expression of b-catenin in the AML cases (Figure 1 ), which did not appear to correlate with the level of expression of CD34 as assessed by flow cytometry, that is, there were cases with high levels of b-catenin and low CD34 expression as well as cases with low levels of b-catenin and high CD34 expression. Normally, in cells not exposed to Wnt signals, b-catenin is complexed with cadherin molecules at the cell membrane and links their intracytoplasmic domain to the actin cytoskeleton. Fractionation of AML blasts showed the presence of b-catenin in the nuclear fraction indicating potential transcriptional activation of this pathway (n ¼ 3) (Figure 1 ).
Development of a technique for high-level transient transfection of primary normal progenitors and AML cells
Establishing whether a signalling pathway is constitutively active in primary tumour cells, compared with their normal counterparts, is often difficult. The mere presence of components of a pathway cannot be used as a surrogate for activity. In order to establish if the Wnt/ b-catenin pathway was active in primary normal CD34 þ cells or in AML blasts, we wished to utilize a technique to assay transcriptional activity using a reporter construct originally used to identify activation of this signalling module in cell lines derived from patients with colon carcinoma (Korinek et al., 1997) . In order to do this, we needed to develop a method of achieving high levels of transfection in these primary cells. First, we investigated if we could transfect normal CD34 þ progenitors using the technique of modified electroporation known as nucleofection (Trompeter et al., 2003) using a GFP expressing plasmid. We found that normal CD34 þ cells rapidly express GFP following nucleofection with transfected cells detected within 3 h (Figure 2 ). Larger plasmids including an Akt-GFP fusion vector were also efficiently transfected with overall transfection levels in CD34 þ cells of 5479% (Figure 2 ). Having established successful transfection in normal progenitors, we used the same technique in primary AML blasts. Mean transfection levels were 3976% (Figure 2 ) and the CD34 þ fraction of AML cells (which includes putative leukaemia-initiating cells) was transfected to a similar degree as the CD34-negative fraction (data not shown). , 1997) . We confirmed that this reporter was functional in the 293T cell line when cotransfected with an active b-catenin mutant ( Figure 3a ). We transfected TOP-FLASH, or the control plasmid FOP-FLASH, into normal CD34 þ progenitors and myeloid leukaemia blasts. In early normal CD34 þ cells (days 1-3 of culture), where bcatenin was detected at the protein level, TOP-FLASH reporter activity averaged 1.570.4 (fold activity relative to that obtained with FOP-FLASH, n ¼ 3 separate donors). b-Catenin is regulated by phosphorylation of N-terminal residues by GSK-3b in a multiprotein complex including APC and axin resulting in its degradation via the proteasome. We found that TOP-FLASH activity in normal CD34 þ cells could be significantly increased by incubation with the GSK-3b
inhibitor lithium chloride (Davies et al., 2000) ( Figure 3b ). Increased TOP-FLASH reporter activity compared with normal progenitors was detected in a high proportion of cases with AML in the absence of any exogenous growth factors ( Figure 3c ). Using an arbitrary cutoff of twice the average seen with normal CD34 þ cells, increased reporter activity was detected in 16 out of 25 cases. Increased activity was seen in 6/7 cases with an activating internal tandem duplication of the Flt3 tyrosine kinase compared with 10/18 without an Flt3 mutation, a difference in incidence that did not reach statistical significance (P ¼ 0.06). To confirm that the TCF/LEF pathway was present and could be regulated in primary AML cells, we incubated blast cells transfected with the TOP-FLASH reporter with purified recombinant Wnt-3a and found an increase in reporter activity ( Figure 3d ). This increase in reporter activity could also be achieved by transfection of a constitutively active mutant b-catenin. Further, we were Effect of expressing a mutant b-catenin on the proliferation and differentiation of normal human CD34 þ progenitors
Having shown that the TCF/LEF pathway is constitutively active in a significant proportion of AML cases, we wished to investigate the impact this could have on normal myeloid development in order to assess its potential role in leukaemogenesis. We expressed a constitutively active b-catenin (S37A mutant) in normal primary human CD34 þ cells by retroviral transduction (Orford et al., 1997) . The S37A b-catenin mutant cannot be fully phosphorylated by GSK-3b and is therefore less susceptible to proteasomal degradation. Using a bicistronic vector expressing GFP from an IRES, CD34 þ cells expressing b-catenin or a control vector were sorted by flow cytometry and incubated in cytokines including GM-CSF and G-CSF in liquid culture (Figure 4 ). Cells were counted and immunophenotyped with CD34, CD11b (to examine granulo-monocytic differ- Normal CD34 þ progenitors expressing retrovirally transduced active b-catenin were also protected from apoptosis with 48% survival at 72 h compared with 17% for control vector expressing cells.
Investigation of potential mechanisms by which b-catenin/ TCF signalling is upregulated in AML
Sequencing of the N-terminal region of b-catenin, which is mutated in colon cancer, in the AML cases did not reveal any abnormality. Further, investigation for mutations in the APC gene did not reveal abnormalities in the regions that are frequently mutated in colon cancer. We found that a significant proportion of AML cases were positive by RT-PCR for the LEF-1 transcription factor, whereas expression in normal progenitors was not detectable ( Figure 5 ). In addition, there was constitutive expression of Wnt-1 and Wnt-2b in a number of AML samples ( Figure 5 ). Both these Wnt family members can activate signalling via the bcatenin pathway. Wnt-10b was expressed in both normal and leukaemic progenitors.
Discussion
The Wnt signalling pathway is a key regulator of a number of embryonic developmental events and contributes to tumour formation when it is constitutively activated (Conacci-Sorrell et al., 2002; Moon et al., 2002; Giles et al., 2003) . In addition to their role in the embryo, Wnts are also involved in stem cell self-renewal and differentiation throughout life. This is best characterized in the intestine where the proliferation and differentiation of stem cells at the base of colonic crypts is controlled by the b-catenin/TCF pathway van de Wetering et al., 2002) . Mutations resulting in constitutive activation of b-catenin/TCF lead to impaired differentiation and the maintenance of a crypt progenitor-like phenotype . b-Catenin/TCF also appears to regulate the epidermal stem cell compartment with activation associated with increased self-renewal and impaired differentiation (Huelsken et al., 2001) . In lymphopoiesis, Wnt/LEF-1 signalling appears to be involved in proliferation of the B-cell precursor compartment (Reya et al., 2000) . There is some recent controversy as to the role of Wnt/b-catenin in haemopoiesis: work from Weissman and colleagues showed that Wnt/b-catenin may play a significant part in regulation of HSC function Willert et al., 2003) . They demonstrated that expression of a mutant b-catenin in murine HSC leads to their expansion in vitro and an increased ability to reconstitute haemopoiesis in transplantation experiments . Overexpression of axin, an inhibitory molecule in this pathway, resulted in inhibition of HSC function . In addition, exposure of HSC to purified Wnt-3a in vitro resulted in their expansion . In contrast, using inducible Cre-loxP-mediated inactivation of b-catenin, Cobas et al. (2004) have shown that bone marrow progenitor self-renewal and multilineage repopulation capabilities are not dependent on this pathway. Wnt-5a has been shown to increase human HSC repopulating ability (Murdoch et al., 2003) , but may also act as a tumour suppressor in haemopoietic tissue (Liang et al., 2003) . This effect may be independent of b-catenin however (Liang et al., 2003) ; indeed Wnt-5a has been shown in some circumstances to oppose the canonical Wnt/b-catenin signalling pathway (Topol et al., 2003) .
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We have found that b-catenin is expressed in primary human CD34 þ progenitor cells and is downregulated with myeloid differentiation such that CD33 þ CD34À cells that are at the myeloblast stage have very low/ undetectable protein levels. Primary AML blasts have a range of expression of b-catenin, and this does not appear to correlate with CD34 expression, indicating that the link of b-catenin downregulation with myeloid differentiation may be uncoupled in leukaemia. In addition, we have found that b-catenin is detectable in the nuclear fraction of AML blasts, which is suggestive of involvement in transcriptional activation (Giles et al., 2003) . These findings of altered expression patterns of b-catenin have also recently been described in progenitor cells from patients with blast-crisis transformation of chronic myeloid leukaemia (CML) (Jamieson et al., 2004) .
Haemopoietic progenitor cell self-renewal and differentiation are mediated by the interaction of a number of transcription factors and cell fate may depend on relatively subtle changes in these pathways. In order to assess the activity of the Wnt pathway in normal CD34 þ progenitors and AML blasts, we measured changes in transcriptional activity of this pathway using a TCF/LEF reporter (Korinek et al., 1997) . This is a well-established technique in other cell types, in particular in colon carcinoma cell lines, but requires efficient transfection of a reporter construct, which is notoriously difficult in primary haemopoietic cells. We utilized the nucleofection technique, which has been reported to be effective in other primary cell types (Lai et al., 2003; Trompeter et al., 2003) , and were able to achieve high levels of transient transfection in both CD34 þ cells and in AML blasts. This showed a low but detectable level of TCF/LEF reporter activity in normal CD34 þ cells. Elevated reporter activity (Xtwo-fold the average of the normal CD34 þ cell level) was found in 16 of 25 cases of AML. In six of seven cases with an Flt3-ITD, there was increased activity but this was not statistically significantly different from those without a mutation. It has been reported that the Wnt pathway can be activated by signalling via hepatocyte growth factor receptor tyrosine kinase (c-met) as well as by the Ron tyrosine kinase (Danilkovitch-Miagkova et al., 2001) . It remains to be seen if Flt3 can directly activate this pathway. Wnt/b-catenin has previously been implicated in the development of human leukaemia: McWhirter et al. (1999) showed that the E2a-Pbx fusion protein found in precursor B-acute lymphoblastic leukaemia (ALL) activates the expression of Wnt-16 resulting in a potential autocrine signalling loop. Chung et al. (2002) showed that b-catenin protein was expressed in leukaemia cell lines and primary cells to varying levels. Inhibition of the Wnt/b-catenin pathway in Jurkat T-lymphoblastic cells impaired proliferation and increased susceptibility to apoptosis in response to One of the defining features of AML is impaired differentiation of the malignant cells to mature granulocytes and monocytes. In some cases, this is associated with specific chromosomal abnormalities affecting transcription factors that play a role in normal myeloid differentiation. These include translocations involving core binding factors such as the AML1-ETO fusion in t(8;21) and the CBFb/MYH11 fusion in inv16 and these fusion proteins have a dominant-inhibitory effect on the product of the remaining normal CBF allele (Kelly and Gilliland, 2002) . We expressed a mutant form of bcatenin (S37A mutant), which cannot be fully phosphorylated by GSK-3b and is therefore less susceptible to proteasomal degradation (Orford et al., 1997) , in normal primary human CD34 þ cells by retroviral transduction. We found that under conditions of maximal cytokine stimulation, progenitor cells expressing mutant b-catenin had impaired myelomonocytic differentiation. There was no significant effect of mutant b-catenin on proliferation under these culture conditions: this could be due to the maximal rate of cell division in response to high cytokine concentrations in vitro. The characteristics of altered self-renewal properties demonstrated by Reya et al. (2003) and abnormal differentiation shown here are typical of cancer 'stem' cells (Reya et al., 2001) . It has been shown that the Wnt/ b-catenin pathway may be abnormally activated in malignancy by a number of different molecular mechanisms. These include the loss of APC or axin ( . We could not detect mutations in b-catenin or APC in our AML samples but could detect aberrant expression of Wnt-1, Wnt-2b and LEF-1. Further work is in progress to characterize other elements of the Wnt/ b-catenin signalling module in these samples. It may be that a number of different upstream genetic lesions can lead to the activation of the Wnt/b-catenin/TCF axis. A large number of b-catenin/TCF target genes have been identified and in colorectal cells include c-myc and cyclin D1 (Giles et al., 2003; Kikuchi, 2003) . Overall, it has been suggested that b-catenin/TCF targets often work to repress differentiation (Giles et al., 2003; Kikuchi, 2003) . Reya et al. (2003) found moderate upregulation of HOXB4 and Notch1 in murine progenitors expressing activated b-catenin. Both these factors have been implicated in stem cell selfrenewal (Varnum-Finney et al., 2000; Antonchuk et al., 2002; Stier et al., 2002) . Preliminary microarray gene expression results from human CD34 þ cells transfected with a mutant b-catenin as detailed above show a reduction in expression of myelomonocytic and erythroid specific genes (M Simon and A Khwaja, unpublished data).
In conclusion, by using experimental techniques designed to examine primary human haemopoietic tissues, we have found that the Wnt/b-catenin/TCF pathway is constitutively active in many cases of AML. We show that activating this pathway in normal progenitors results in impaired myelomonocytic differentiation. In conjunction with recent data showing that the Wnt/b-catenin pathway can promote the selfrenewal of normal stem cells and leukaemic progenitors Jamieson et al., 2004) , these results suggest that aberrant activation of this pathway may contribute significantly to the malignant phenotype of AML, which is typified by impaired differentiation and dysregulated self-renewal and survival signalling. The identification of Wnt/b-catenin/TCF abnormalities in AML provides a novel target for the development of rationally designed therapeutics.
Materials and methods
CD34 and AML cell culture
Human CD34 þ cells were isolated from the peripheral blood of haematologically normal individuals undergoing stem cell mobilization by positive immunomagnetic selection (Watts et al., 2002) . Samples were obtained according to local ethics committee guidelines. CD34 þ cells were induced to undergo myeloid differentiation as previously described in the presence of SCF, IL-3, GM-CSF and G-CSF (Watts et al., 2002) . AML blasts were isolated from the peripheral blood or bone marrow of patients at first presentation, frozen in liquid nitrogen in 10% DMSO and recovered for experiments. Samples with poor recovery or very low cell numbers were discarded and constituted five of 31 samples leaving 26 cases for evaluation (Table 1) . Samples constituted more than 90% blasts. There were no patients with FAB types M3 or M6 and seven cases had Flt3-ITD detectable by PCR (Kottaridis et al., 2001 ). Only one patient had an Flt3-D835 mutation -this was in addition to an Flt3-ITD. Cells were routinely cultured in RPMI þ 10% FCS.
Cell lysates and Western blots
Total cell lysates and nuclear extracts were made as previously described (Ardeshna et al., 2000) . Antibodies used were b-catenin (BD-Transduction Labs), tubulin (Roche), IkBa (Santa Cruz) and Rac1 (BD-Transduction Labs).
Nucleofection
The nucleofector device and human CD34 kits were obtained from Amaxa (Koeln, Germany) and used in accordance with the manufacturer's protocol (U-08). For GFP expression, 1-5 Â 10 6 CD34 þ cells or AML blasts were used with 1-2 mg of the pEGFPN1 plasmid (Clontech) or a plasmid encoding an Akt-GFP fusion protein (provided by J Downward, CRUK, London). Cells were analysed by flow cytometry (Epics, Beckman-Coulter) or fluorescence microscopy.
Reporter assays
The TOP-FLASH and FOP-FLASH luciferase reporter constructs were provided by H Clevers (Utrecht, Holland) and the Renilla luciferase plasmid (pRL-CMV) was obtained from Promega. A total of 1-5 Â 10 6 CD34 þ cells or AML blasts were nucleofected with 2 mg of either TOP-FLASH or FOP-FLASH plus 0.4 mg of pRL-CMV and incubated overnight in RPMI þ 10% FCS for AML cells or IMDM þ 20% FCS supplemented with or without cytokines for normal CD34 þ cells. TOP-FLASH or FOP-FLASH activity was corrected for Renilla activity using the Dual Luciferase Kit (Promega) and results are expressed as a ratio of corrected TOP-FLASH/FOP-FLASH. The axin construct was kindly provided by Dr F Costantini (Columbia University, New York) (Fagotto et al., 1999) . Wnt-3a was purchased from R&D Systems.
Retroviral transduction and flow cytometry
The S37A b-catenin mutant was provided by S Byers (Georgetown University, Washington, DC, USA) and was cloned into the PMX-IRES-GFP vector. FLYRD18 producer cell lines expressing empty vector or b-catenin were generated as described (Kelly et al., 2000) and flow-sorted twice to obtain high GFP expressing pools using an EPICS Elite flow cytometer (Beckman-Coulter). Peripheral blood CD34 þ cells were prestimulated for 48 h in IMDM þ 20% FCS with 50 ng/ ml SCF, 50 ng/ml Flt3-L, 10 ng/ml IL-3 and 10 ng/ml IL-6. Six-well plates were coated with Retronectin (Takara, Shiga, Japan) at 20 mg/ml for 2 h, blocked with 2% BSA in PBS for 1 h, washed and loaded twice with retroviral supernatant from FLYRD18 producer cells at 30 min intervals. CD34 þ cells were then added and the infection repeated 24 h later. Transduction rates ranged between 15 and 65%. GFP-positive cells were then isolated by flow-sorting 48 h after the first infection. Cells were immunophenotyped at intervals using PEconjugated CD34 (BD Pharmingen), CD33, CD14 and CD11b (all Dako).
PCR and RT-PCR
Identification of Flt3-ITD, D835 mutation (Kottaridis et al., 2002) and N-terminal b-catenin mutations (Abraham et al., 2002) by PCR was as described. APC mutations were screened for by using heteroduplex analysis. DNA was amplified using Optimase Polymeraset (Transgenomic Limited, Crewe, UK). Primers for APC covering nt 762-1181 (1F 5 
GAAGATG-3
0 , 2R 5 0 -CTATCTGGAAGATCACTGGGG-3 0 ) and nt 4250-4640 (3F 5 0 -CGTTCAGAGTGAACCATG CAG-3 0 , 3R 5 0 -CCCATTGTCATTTTCCTGAAC-3 0 ) were used. PCR products were gel purified, denatured and analysed using denaturing HPLC on a Transgenomic WAVEt. Patterns from patient samples were compared with those from DNA from normals and from the SW480 colon carcinoma cell line as a positive control. PCR products from samples with altered patterns were directly sequenced using the CEQt DTCS Quick Start kit and a CEQt 8000 Genetic Analysis System (Beckman Coulter Inc., Fullerton, USA).
cDNA was generated from RNA isolated from normal or leukaemic cells using an Ambion kit (Ambion, Huntingdon, UK) and PCR carried out for LEF-1 (5 0 -TTCTCCACCCA TCCCGAGAAC-3 0 forward primer and 5 0 -CTGAGGCTTC ACGTGCATTTAG-3 0 reverse primer), Wnt-1 (5 0 -ATGGGG CTCTGGGCGCTGTTG-3 0 forward and 5 0 -CACACGTGCA GGATTCGATGG-3 0 reverse), Wnt-2b (5 0 -CACCTGCTGG CGTGCACTCTCAGA-3 0 forward and 5 0 -GGGCTTTGCAA GTATGGACGTCCACAGTA-3 0 reverse) andWnt-10b (5 0 -GGAGGGCGGCCCCAGAGTTCC-3 0 forward and 5 0 -AAG CTGCCACAGCCATCCAACAGG-3 0 reverse).
